(4R)-4-ethyl-1,3-oxazolidin-2-one → (R)-4-ethyl-3-[5-(4-p-tolyloxypiperidine-1-carbonyl)pyridin-2-yl]oxazolidin-2-one

HRID 1804181Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1804181
Br[C:2]1[N:7]=[CH:6][C:5]([C:8]([N:10]2[CH2:15][CH2:14][CH:13]([O:16][C:17]3[CH:22]=[CH:21][C:20]([CH3:23])=[CH:19][CH:18]=3)[CH2:12][CH2:11]2)=[O:9])=[CH:4][CH:3]=1.[CH2:24]([C@@H:26]1[CH2:30][O:29][C:28](=[O:31])[NH:27]1)[CH3:25]>>[CH2:24]([C@@H:26]1[CH2:30][O:29][C:28](=[O:31])[N:27]1[C:2]1[CH:3]=[CH:4][C:5]([C:8]([N:10]2[CH2:15][CH2:14][CH:13]([O:16][C:17]3[CH:22]=[CH:21][C:20]([CH3:23])=[CH:19][CH:18]=3)[CH2:12][CH2:11]2)=[O:9])=[CH:6][N:7]=1)[CH3:25]

Komponenten

3

Edukt 2

HCID 641503(4R)-4-ethyl-1,3-oxazolidin-2-oneHCID 58484591(6-Bromopyridin-3-yl)[4-(p-tolyloxy)piperidin-1-yl]methanone

Produkt 1

HCID 46190176(R)-4-ethyl-3-[5-(4-p-tolyloxypiperidine-1-carbonyl)pyridin-2-yl]oxazolidin-2-oneAusbeute 20 %

Versuchsvorschrift

By reaction and treatment in the same manner as in Example 40 and using (6-bromopyridin-3-yl)(4-p-tolyloxypiperidin-1-yl)methanone (1.2 g) described in Preparation Example 28 and (R)-4-ethyloxazolidin-2-one (525 mg) described in Preparation Example 26, the title compound (262 mg) was obtained.

Aufarbeitung

  1. customBy reaction and treatment in the same manner as in Example 40
  2. customdescribed in Preparation Example 26

Quellen und Nachweise

ORD-Eintrag
ord-6c397034ad944e5988bf103c627dc2b2
Quelldatensatz
uspto-grants-2013_01
Patentnummer
US08354401B2

Notizen zur Reaktion

Wird geladen…